A citation-based method for searching scientific literature

Christopher P Childers, Kimberly K Childers, Melinda Maggard-Gibbons, James Macinko. J Clin Oncol 2017
Times Cited: 128







List of co-cited articles
567 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Hereditary gynecologic cancers.
David Mutch, Lynette Denny, Michael Quinn. Int J Gynaecol Obstet 2014
10
10


Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
Spring Holter, Ayelet Borgida, Anna Dodd, Robert Grant, Kara Semotiuk, David Hedley, Neesha Dhani, Steven Narod, Mohammad Akbari, Malcolm Moore,[...]. J Clin Oncol 2015
197
1

Prevalence of family history of breast and ovarian cancer in a single primary care practice using a self-administered questionnaire.
Kevin S Hughes, Constance Roche, Curtis T Campbell, Nancy Siegel, Lisa Salisbury, Amy Chekos, Maya S Katz, Erica Edell. Breast J 2003
38
2

Interrater reliability: the kappa statistic.
Mary L McHugh. Biochem Med (Zagreb) 2012
1

Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.
Therese B Bevers, Mark Helvie, Ermelinda Bonaccio, Kristine E Calhoun, Mary B Daly, William B Farrar, Judy E Garber, Richard Gray, Caprice C Greenberg, Rachel Greenup,[...]. J Natl Compr Canc Netw 2018
101
1

The heritability of prostate cancer in the Nordic Twin Study of Cancer.
Jacob B Hjelmborg, Thomas Scheike, Klaus Holst, Axel Skytthe, Kathryn L Penney, Rebecca E Graff, Eero Pukkala, Kaare Christensen, Hans-Olov Adami, Niels V Holm,[...]. Cancer Epidemiol Biomarkers Prev 2014
100
1

BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.
Z Kote-Jarai, D Leongamornlert, E Saunders, M Tymrakiewicz, E Castro, N Mahmud, M Guy, S Edwards, L O'Brien, E Sawyer,[...]. Br J Cancer 2011
218
1

Screen-positive rates and agreement among six family history screening protocols for breast/ovarian cancer in a population-based cohort of 21- to 55-year-old women.
Glenn E Palomaki, Monica R McClain, Klaus Steinort, Randa Sifri, Leigh LoPresti, James E Haddow. Genet Med 2006
16
6

Epidemiology of Prostate Cancer.
Prashanth Rawla. World J Oncol 2019
322
1

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Mary B Daly, Tuya Pal, Michael P Berry, Saundra S Buys, Patricia Dickson, Susan M Domchek, Ahmed Elkhanany, Susan Friedman, Michael Goggins, Mollie L Hutton,[...]. J Natl Compr Canc Netw 2021
13
7

An approach to the patient with a family history of breast cancer.
Judy Kirk, Meagan Brennan, Nehmet Houssami, Owen Ung. Aust Fam Physician 2006
3
33

Prevalence of family histories of breast cancer in the general population and the incidence of related seeking of health care.
C E Jacobi, M A Jonker, N J D Nagelkerke, J C van Houwelingen, G H de Bock. J Med Genet 2003
11
9

Population prevalence of individuals meeting criteria for hereditary breast and ovarian cancer testing.
Samantha Greenberg, Saundra S Buys, Sandra L Edwards, Whitney Espinel, Alison Fraser, Amanda Gammon, Brent Hafen, Kimberly A Herget, Wendy Kohlmann, Camille Roundy,[...]. Cancer Med 2019
5
20

Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
Diana M Eccles, Judith Balmaña, Joe Clune, Birgit Ehlken, Annegret Gohlke, Ceri Hirst, Danielle Potter, Claudia Schroeder, Jerzy E Tyczynski, Encarnacion B Gomez Garcia. Adv Ther 2016
30
3

Little value from including cousins in individual risk assessment of hereditary breast cancer: a simulation study.
M A Jonker, G H de Bock, W E Hoogendoorn, C J van Asperen, J C van Houwelingen. J Med Genet 2003
2
50


Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
F Aloraifi, M Alshehhi, T McDevitt, N Cody, M Meany, A O'Doherty, C M Quinn, A J Green, A Bracken, J G Geraghty. Eur J Surg Oncol 2015
7
14

Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.
K A Metcalfe, A Finch, A Poll, D Horsman, C Kim-Sing, J Scott, R Royer, P Sun, S A Narod. Br J Cancer 2009
68
1

Identification of hereditary cancer in the general population: development and validation of a screening questionnaire for obtaining the family history of cancer.
Natalia Campacci, Juliana O de Lima, André L Carvalho, Rodrigo D Michelli, Rafael Haikel, Edmundo Mauad, Danilo V Viana, Matias E Melendez, Fabiana de L Vazquez, Cleyton Zanardo,[...]. Cancer Med 2017
6
16

Contribution of extended family history in assessment of risk for breast and colon cancer.
Benjamin L Solomon, Todd Whitman, Marie E Wood. BMC Fam Pract 2016
7
14

Screen positive rates among six family history screening protocols for breast/ovarian cancer in four cohorts of women.
Monica R McClain, Glenn E Palomaki, Heather Hampel, Judith A Westman, James E Haddow. Fam Cancer 2008
8
12

Prevalence of family history of breast, colorectal, prostate, and lung cancer in a population-based study.
P L Mai, L Wideroff, M H Greene, B I Graubard. Public Health Genomics 2010
22
4

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.
Marilyn M Li, Michael Datto, Eric J Duncavage, Shashikant Kulkarni, Neal I Lindeman, Somak Roy, Apostolia M Tsimberidou, Cindy L Vnencak-Jones, Daynna J Wolff, Anas Younes,[...]. J Mol Diagn 2017
510
1

Sample Tracking Using Unique Sequence Controls.
Richard A Moore, Thomas Zeng, T Roderick Docking, Ian Bosdet, Yaron S Butterfield, Sarah Munro, Irene Li, Lucas Swanson, Elizabeth R Starks, Kane Tse,[...]. J Mol Diagn 2020
2
50

Advances in the use of PARP inhibitor therapy for breast cancer.
Kelly E McCann, Sara A Hurvitz. Drugs Context 2018
54
1

Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data.
Valentina Boeva, Tatiana Popova, Maxime Lienard, Sebastien Toffoli, Maud Kamal, Christophe Le Tourneau, David Gentien, Nicolas Servant, Pierre Gestraud, Thomas Rio Frio,[...]. Bioinformatics 2014
70
1

Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls.
Justin M Zook, Brad Chapman, Jason Wang, David Mittelman, Oliver Hofmann, Winston Hide, Marc Salit. Nat Biotechnol 2014
410
1

The mutational constraint spectrum quantified from variation in 141,456 humans.
Konrad J Karczewski, Laurent C Francioli, Grace Tiao, Beryl B Cummings, Jessica Alföldi, Qingbo Wang, Ryan L Collins, Kristen M Laricchia, Andrea Ganna, Daniel P Birnbaum,[...]. Nature 2020
1

Standard mutation nomenclature in molecular diagnostics: practical and educational challenges.
Shuji Ogino, Margaret L Gulley, Johan T den Dunnen, Robert B Wilson. J Mol Diagn 2007
94
1

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
Kara N Maxwell, Bradley Wubbenhorst, Brandon M Wenz, Daniel De Sloover, John Pluta, Lyndsey Emery, Amanda Barrett, Adam A Kraya, Ioannis N Anastopoulos, Shun Yu,[...]. Nat Commun 2017
95
1

Counting absolute numbers of molecules using unique molecular identifiers.
Teemu Kivioja, Anna Vähärautio, Kasper Karlsson, Martin Bonke, Martin Enge, Sten Linnarsson, Jussi Taipale. Nat Methods 2011
478
1


Molecular targeted therapy: Treating cancer with specificity.
Yeuan Ting Lee, Yi Jer Tan, Chern Ein Oon. Eur J Pharmacol 2018
148
1

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
Daniel G Coit, John A Thompson, Mark R Albertini, Christopher Barker, William E Carson, Carlo Contreras, Gregory A Daniels, Dominick DiMaio, Ryan C Fields, Martin D Fleming,[...]. J Natl Compr Canc Netw 2019
141
1


Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays.
Radoje Drmanac, Andrew B Sparks, Matthew J Callow, Aaron L Halpern, Norman L Burns, Bahram G Kermani, Paolo Carnevali, Igor Nazarenko, Geoffrey B Nilsen, George Yeung,[...]. Science 2010
742
1

Personalised cancer medicine.
Sarah E Jackson, John D Chester. Int J Cancer 2015
134
1


Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories.
Victoria M Raymond, Stacy W Gray, Sameek Roychowdhury, Steve Joffe, Arul M Chinnaiyan, D Williams Parsons, Sharon E Plon. J Natl Cancer Inst 2015
49
2

A clinically validated diagnostic second-generation sequencing assay for detection of hereditary BRCA1 and BRCA2 mutations.
Ian E Bosdet, T Roderick Docking, Yaron S Butterfield, Andrew J Mungall, Thomas Zeng, Robin J Coope, Erika Yorida, Katie Chow, Miruna Bala, Sean S Young,[...]. J Mol Diagn 2013
22
4

Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH.
Aung Ko Win, Jeanette C Reece, James G Dowty, Daniel D Buchanan, Mark Clendenning, Christophe Rosty, Melissa C Southey, Joanne P Young, Sean P Cleary, Hyeja Kim,[...]. Int J Cancer 2016
47
2


fastp: an ultra-fast all-in-one FASTQ preprocessor.
Shifu Chen, Yanqing Zhou, Yaru Chen, Jia Gu. Bioinformatics 2018
1

Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
Bryce A Seifert, Julianne M O'Daniel, Krunal Amin, Daniel S Marchuk, Nirali M Patel, Joel S Parker, Alan P Hoyle, Lisle E Mose, Andrew Marron, Michele C Hayward,[...]. Clin Cancer Res 2016
37
2

Analysis of TP53 mutation status in human cancer cell lines: a reassessment.
Bernard Leroy, Luc Girard, Antoinette Hollestelle, John D Minna, Adi F Gazdar, Thierry Soussi. Hum Mutat 2014
98
1

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.
Garrett M Frampton, Alex Fichtenholtz, Geoff A Otto, Kai Wang, Sean R Downing, Jie He, Michael Schnall-Levin, Jared White, Eric M Sanford, Peter An,[...]. Nat Biotechnol 2013
1

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
Donavan T Cheng, Talia N Mitchell, Ahmet Zehir, Ronak H Shah, Ryma Benayed, Aijazuddin Syed, Raghu Chandramohan, Zhen Yu Liu, Helen H Won, Sasinya N Scott,[...]. J Mol Diagn 2015
855
1

Anchored multiplex PCR for targeted next-generation sequencing.
Zongli Zheng, Matthew Liebers, Boryana Zhelyazkova, Yi Cao, Divya Panditi, Kerry D Lynch, Juxiang Chen, Hayley E Robinson, Hyo Sup Shim, Juliann Chmielecki,[...]. Nat Med 2014
454
1

Integrative genomics viewer.
James T Robinson, Helga Thorvaldsdóttir, Wendy Winckler, Mitchell Guttman, Eric S Lander, Gad Getz, Jill P Mesirov. Nat Biotechnol 2011
1


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.